EasySep™ Release Human CD45 Positive Selection Kit

Immunomagnetic positive selection kit using particle release technology

EasySep™ Release Human CD45 Positive Selection Kit

Immunomagnetic positive selection kit using particle release technology

From: 735 USD
Catalog #
100-0105_C
Immunomagnetic positive selection kit using particle release technology

Product Advantages


  • Highly purified CD45+ cells isolated in less than 45 minutes

  • No-wash removal of EasySep™ Releasable RapidSpheres™

What's Included

  • EasySep™ Release Human CD45 Positive Selection Kit (Catalog #100-0105)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
  • RoboSep™ Release Human CD45 Positive Selection Kit (Catalog #100-0108)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
    • EasySep™ EasyTube™-14 (Catalog #20128)
  • EasySep™ Release Human CD45 Positive Selection Kit for Humanized Mice (Catalog #100-0107)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
    • Normal Rat Serum, 2 mL
    • EasySep™ Mouse FcR Blocker, 0.5 mL
  • RoboSep™ Release Human CD45 Positive Selection Kit for Humanized Mice (Catalog #100-0109)
    • EasySep™ Release Human CD45 Positive Selection Cocktail, 0.5 mL
    • EasySep™ Releasable RapidSpheres™, 1 mL
    • EasySep™ Release Buffer (Concentrate), 6 x 1 mL
    • Normal Rat Serum, 2 mL
    • EasySep™ Mouse FcR Blocker, 0.5 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125) x 2
    • EasySep™ EasyTube™-14 (Catalog #20128) x 2

Overview

The EasySep™ Release Human CD45 Positive Selection Kit is designed to isolate CD45+ leukocytes from single-cell suspensions of primary human tissues and tumors, or tissues and tumor xenografts from humanized mice, by immunomagnetic positive selection.

Desired cells are labeled with antibodies and magnetic particles, and separated without columns using an EasySep™ magnet. Unwanted cells are simply poured off, while desired cells remain in the tube. Then, bound magnetic particles are removed from the EasySep™-isolated CD45+ cells, which are immediately available for downstream applications. Following cell isolation with this EasySep™ Release kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands.
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• EasyPlate™ EasySep™ Magnet (Catalog #18102)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
Leukocytes
Species
Human, Mouse
Sample Source
Other, Tumor
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Cancer, Immunology

Data Figures

Using the EasySep™ Release Human CD45 Positive Selection Kit, the CD45+ TIL purities of the start and final isolated fractions are 5.5% and 96.0%, respectively.

Figure 1. EasySep™ Release Human CD45 Positive Selection Kit

Starting with a single-cell suspension of a human breast cancer tumor xenograft (MDA-MB-231) sample from an NRG-3GS humanized mouse, the CD45+ TIL purities of the start and final isolated fractions are 5.5% and 96.0%, respectively.
NOTE: Cell debris and dead cells were excluded from the analysis based on DRAQ5™ and DAPI fluorescence.

Using PBMCs as a startnig sample, this t-SNE plot shows that EasySep™-isolated CD45+ cells are representative of the starting leukocyte population.

Figure 2. EasySep™-Isolated CD45+ Cells are Representative of the Starting Leukocyte Population

Mass cytometry data comparing the composition of immune subsets in PBMCs and EasySep™-isolated cells from the same donor. Starting with whole blood, PBMCs were prepared by density gradient centrifugation using Lymphoprep™. To compare immune subset composition pre- and post-EasySep™ isolation, a fraction of the PBMCs was further isolated using EasySep™ Release Human CD45 Positive Selection Kit and the pre- and post-isolated fractions were assessed by mass cytometry (CyTOF®). t-SNE plots of cells stained with 19 markers and analyzed by CyTOF® are shown (n = 1).

PBMCs pre- and post-EasySep™ isolation were incubated in peptide pools (CEF, CPI, or PHA) and a robust population of IFN-gamma-producing cells in these respective samples are visible on ELISpot plates, showing that EasySep™-isolated CD45+ cells produce IFN-gamma in response to antigen and mitogen stimulation.

Figure 3. EasySep™-Isolated CD45+ Cells Produce IFN-gamma in Response to Antigen and Mitogen Stimulation

PBMCs pre- and post-EasySep™ isolation were incubated for 24 hours in the presence of peptide pools (CEF for antigen-specific CD8+ T cell response and CPI for antigen-specific CD4+ T cell response) or mitogen (phytohemagglutinin [PHA]). Following incubation, ELISpot plates were processed and IFN-gamma-producing cells were counted using an AID ELISpot reader. Representative images of ELISpot assays are shown (n = 3).

CD45+ cells isolated from spleens, lungs, bone marrow, MDA MB231 tumors, and SKOV3 tumors using EasySep™ are highly purified.

Figure 4. CD45+ Cells Isolated by EasySep™ from Various Tissues Are Highly Purified

A humanized mouse tumor model was generated by engraftment of human CD34+ hematopoietic stem and progenitor cells into NRG-3GS mice followed by xenotransplantation with human cancer cell lines, MDA-MB-231 (breast cancer) or SKOV-3 (ovarian carcinoma). Starting with a single-cell suspension of spleens, lungs, bone marrow, or tumors, human CD45+ leukocytes were isolated using EasySep™ Release Human CD45 Positive Selection Kit. The starting frequencies and isolated purities of human CD45+ cells of individual experiments and averages are shown.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0105
Lot #
All
Language
English
Catalog #
100-0107
Lot #
All
Language
English
Catalog #
100-0108
Lot #
All
Language
English
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0105
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0105
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0105
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
100-0107
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0108
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
100-0109
Lot #
All
Language
English
Document Type
Safety Data Sheet 6
Catalog #
100-0109
Lot #
All
Language
English

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.